← Back to Search

Checkpoint Inhibitor

Pembrolizumab for Gastroesophageal Junction Adenocarcinoma

Phase < 1
Waitlist Available
Led By Jaffer A Ajani
Research Sponsored by M.D. Anderson Cancer Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
The subject (or legally acceptable representative if applicable) provides written informed consent for the trial. The subject may also provide consent for future biomedical research. However the subject may participate in the main trial without participating in future biomedical research.
Be willing and able to provide written informed consent/assent for the trial.
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 4 years
Awards & highlights

Study Summary

This trial is testing how well pembrolizumab works in treating patients with gastroesophageal adenocarcinoma.

Eligible Conditions
  • Gastroesophageal Junction Adenocarcinoma
  • Esophageal Adenocarcinoma
  • Gastric Cancer
  • Esophageal Cancer

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 4 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 4 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Objective response rate (ORR)
Secondary outcome measures
Disease control rate
Duration of response
Incidence of adverse events
+3 more

Side effects data

From 2024 Phase 2 trial • 57 Patients • NCT03004183
21%
Fatigue
13%
Nausea
11%
Back pain
9%
Shortness of Breath
9%
Anemia
9%
Abdominal pain
9%
Diarrhea
7%
Kidney Injury and/or Infection
7%
Pneumonia
7%
Dyspnea
7%
Weight Loss
5%
Malnutrition, Hypercalcemia and Weakness
5%
Pneumothorax
5%
Activated partial thromboplastin time prolonged
5%
Intractable pain, back pain, hip pain
4%
Pleural effusion
4%
Atrial fibrillation with rapid ventricular response
2%
Skin rash
2%
Thrombocytopenia
2%
Respiratory failure
2%
colitis
100%
80%
60%
40%
20%
0%
Study treatment Arm
Single Arm

Trial Design

1Treatment groups
Experimental Treatment
Group I: Treatment (pembrolizumab)Experimental Treatment1 Intervention
Patients receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 35 cycles in the absence of disease progression or unacceptable toxicity.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Pembrolizumab
FDA approved

Find a Location

Who is running the clinical trial?

M.D. Anderson Cancer CenterLead Sponsor
2,958 Previous Clinical Trials
1,798,440 Total Patients Enrolled
National Cancer Institute (NCI)NIH
13,609 Previous Clinical Trials
40,915,637 Total Patients Enrolled
Jaffer A AjaniPrincipal InvestigatorM.D. Anderson Cancer Center
2 Previous Clinical Trials
23 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How many enrollees are part of this research endeavor?

"Affirmative. According to information hosted on clinicaltrials.gov, this medical research is actively seeking participants since its inception on February 9th 2018 and the last update was posted in December 5th 2022. This trial needs 15 individuals from a single location for participation."

Answered by AI

Are there still opportunities to enroll in this clinical experiment?

"Affirmative, the clinicaltrials.gov website attests that this medical study is currently recruiting patients. It was initially posted on February 9th 2018 and revised on December 5th 2022. The research team seeks to enroll 15 people at one of its sites."

Answered by AI

What types of diseases can be addressed with the administration of Pembrolizumab?

"Pembrolizumab is most frequently utilized in the treatment of malignancies. In addition, it may be prescribed to treat unresectable melanoma and microsatellite instability high conditions that have progressed despite chemotherapy treatment."

Answered by AI

What data has been collected from previous investigations into Pembrolizumab?

"At present, clinical trials of Pembrozulizumab are being conducted in 961 different locations. Of these studies, 122 have reached Phase 3 and the overwhelming majority (36177) are located near Houston, Texas."

Answered by AI
~1 spots leftby Mar 2025